StockNews.com Begins Coverage on Aptose Biosciences (NASDAQ:APTO)

StockNews.com assumed coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research report issued to clients and investors on Tuesday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $2.00 price objective on shares of Aptose Biosciences in a research report on Tuesday, December 10th.

Aptose Biosciences Stock Down 2.0 %

APTO stock opened at $0.24 on Tuesday. Aptose Biosciences has a twelve month low of $0.13 and a twelve month high of $2.60. The company has a market cap of $14.21 million, a PE ratio of -0.08 and a beta of 1.06. The business’s 50-day simple moving average is $0.28 and its 200 day simple moving average is $0.44.

Institutional Investors Weigh In On Aptose Biosciences

A hedge fund recently bought a new stake in Aptose Biosciences stock. Armistice Capital LLC purchased a new stake in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned 9.46% of Aptose Biosciences at the end of the most recent reporting period. Institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.